MWNA
AGTC

Marshall Wace North America’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Marshall Wace North America’s Portfolio AGTC Stock Details AGTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-19,048
Closed -$86K – 1706
2019
Q4 		$86K Buy
19,048
+8,831
+86% +$27.9K ﹤0.01% 1075
2019
Q3 		$43K Buy
+10,217
New +$36.9K ﹤0.01% 1177

Other funds holding AGTC

IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Marshall Wace North America's AGTC Position: Q1 2020 in Review

Marshall Wace North America sold out of Applied Genetic Technologies Corporation (AGTC) in Q1 2020, closing a stake of 19,048 shares — an estimated $86K sold.

Marshall Wace North America first reported a position in AGTC in Q3 2019 and held it in 2 quarters. The position peaked at $86K in Q4 2019. 59 funds tracked by Wall St. Rank hold AGTC as of Q1 2020.

  • Marshall Wace North America reported no remaining Applied Genetic Technologies Corporation position as of Q1 2020 after selling out during the quarter.
  • Marshall Wace North America sold 19,048 Applied Genetic Technologies Corporation shares in Q1 2020, an estimated $86K.
  • Marshall Wace North America first reported a position in Applied Genetic Technologies Corporation in Q3 2019 and held it in 2 quarters.
  • Marshall Wace North America's Applied Genetic Technologies Corporation position peaked at $86K in Q4 2019.
  • 59 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.